GC Biopharma Corp. Statistics
Want to see KR:006280 full AI Analyst Report?
GC Biopharma Corp. (006280) Stock Statistics & Valuation Metrics
Total Valuation
GC Biopharma Corp. has a market cap or net worth of KRW 1.51T. The enterprise value is KRW 2.17T.
- Market Cap
- KRW 1.51T
- Enterprise Value
- KRW 2.17T
Share Statistics
GC Biopharma Corp. has 11,686,538 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 11,686,538
- Owned by Insiders
- ―
- Owned by Institutions
- 5.74%
Financial Efficiency
GC Biopharma Corp.’s return on equity (ROE) is -0.00 and return on invested capital (ROIC) is 2.33%.
- Return on Equity (ROE)
- -0.00
- Return on Assets (ROA)
- -0.00
- Return on Invested Capital (ROIC)
- 2.33%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 846.99M
- Profits Per Employee
- -1.99M
- Employee Count
- 2,351
- Asset Turnover
- 0.67
- Inventory Turnover
- 1.63
Valuation Ratios
The current PE Ratio of GC Biopharma Corp. is 9.98. GC Biopharma Corp.’s PEG ratio is -0.06.
- PE Ratio
- 9.98
- PS Ratio
- 0.80
- PB Ratio
- 1.17
- Price to FCF
- 20.77
- Price to Operating Cash Flow
- 7.87
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, GC Biopharma Corp. had revenue of 1.99T and earned -4.67B in profits. Earnings per share was -409.51.
- Revenue
- 1.99T
- Gross Profit
- 536.00B
- Operating Income
- 67.81B
- Pretax Income
- -35.33B
- Net Income
- -4.67B
- EBITDA
- 155.46B
- Earnings Per Share (EPS)
- -409.51
Cash Flow
In the last 12 months, operating cash flow was 184.28B and capital expenditures -111.65B, giving a free cash flow of 72.64B billion.
- Operating Cash Flow
- 184.28B
- Free Cash Flow
- 72.64B
- Free Cash Flow per Share
- 6623.85
Dividends & Yields
GC Biopharma Corp. pays an annual dividend of ―, resulting in a dividend yield of 1.14%
- Dividend Per Share
- ―
- Dividend Yield
- 1.14%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.82%
- Earnings Yield
- 9.86%
Stock Price Statistics
- Beta
- 0.10
- 52-Week Price Change
- -0.30%
- 50-Day Moving Average
- 129628.00
- 200-Day Moving Average
- 134986.58
- Relative Strength Index (RSI)
- 47.78
- Average Volume (3m)
- 24.08K
Important Dates
GC Biopharma Corp. upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
GC Biopharma Corp. as a current ratio of 1.20, with Debt / Equity ratio of 80.67%
- Current Ratio
- 1.20
- Quick Ratio
- 0.42
- Debt to Market Cap
- 0.48
- Net Debt to EBITDA
- 6.00
- Interest Coverage Ratio
- 1.35
Taxes
In the past 12 months, GC Biopharma Corp. has paid -5.65B in taxes.
- Income Tax
- -5.65B
- Effective Tax Rate
- 0.16
Enterprise Valuation
GC Biopharma Corp. EV to EBITDA ratio is 18.30, with an EV/FCF ratio of 33.09.
- EV to Sales
- 1.28
- EV to EBITDA
- 18.30
- EV to Free Cash Flow
- 33.09
- EV to Operating Cash Flow
- 13.04
Balance Sheet
GC Biopharma Corp. has KRW 44.66B in cash and marketable securities with KRW 938.85B in debt, giving a net cash position of -KRW 894.19B billion.
- Cash & Marketable Securities
- KRW 44.66B
- Total Debt
- KRW 938.85B
- Net Cash
- -KRW 894.19B
- Net Cash Per Share
- -KRW 76.51K
- Tangible Book Value Per Share
- KRW 87.14K
Margins
Gross margin is 18.65%, with operating margin of 3.57%, and net profit margin of 7.60%.
- Gross Margin
- 18.65%
- Operating Margin
- 3.57%
- Pretax Margin
- 10.19%
- Net Profit Margin
- 7.60%
- EBITDA Margin
- 7.00%
- EBIT Margin
- 3.57%
Analyst Forecast
The average price target for GC Biopharma Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.99%
- EPS Growth Forecast
- 177.51%
Scores
- Smart Score
- ―
- AI Score
- 54

